We are pleased to share that the first patient in Kodiak’s phase I trial was treated by Dr. Pravin Dugel of the Retinal Consultants of Arizona. The injection was uneventful. Day 2 assessment was within normal limits with no signs of inflammation and with clear ocular media. Kodiak is A Phase I Open Label, Multi-center […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-07-14 14:20:272018-07-14 14:20:27Dr. Pravin U. Dugel Treats First Patient with KSI-301
Dr. Derek Kunimoto visits the AZTV studios to discuss CentraSight’s Implantable Telescope for people with end-stage macular degeneration (wet and dry). For more information, call 602-222-2221 or visit www.CentraSight.com. Age-related macular degeneration (AMD) is the most common cause of severe vision loss in patients over 65. This condition involves a breakdown of the macula, the central […]
Dr. Pravin U. Dugel – Ocular Surgery News U.S. Edition, June 25, 2018 Unmet needs and new options There are unmet needs for DME, mainly related to the high rate of poor responders and the burden of frequent injections. “There are still patients that have suboptimal improvement, so better efficacy is still an unmet need. […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-06-26 21:50:282018-06-26 21:50:28Ocular Surgery News: Treatment of DME poses complex choices, strives to overcome limitations
According to the American Academy of Ophthalmology, approximately 37 million adults in America have age-related macular degeneration, cataract, diabetic retinopathy, or glaucoma, all of which can cause visual impairment or blindness. However, recent studies show that making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. In support […]
Pravin U. Dugel, MD, discusses the HAWK and HARRIER studies, particularly with regard to whether the disease activity assessment done at week 16 can predict which patients can be extended to 12 weeks. He also explains why this is important from a clinical standpoint. Interview from the 2018 ARVO Annual Meeting where leading experts recap […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-05-03 04:08:472018-05-03 04:08:47Dr. Pravin U. Dugel: Predictive Data From the HAWK and HARRIER Studies (Video)
The ideal candidate will possess the following. Ophthalmology experience preferred, but willing to train the right candidate with Medical Assistant Experience. Medical Assistant must possess certification from an accredited program Must be able to work flexible hours and be able to travel via car or plane throughout the state. Photography (FA and OCT) experience helpful Must […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-04-19 17:38:342018-04-19 17:38:34Retinal Consultants of Arizona is Now Hiring Ophthalmic Technicians to Travel with our Amazing Physicians and Staff!
These novel strategies may change DME treatment paradigm By: Michelle Dalton, ELS; Reviewed by Pravin U. Dugel, MD There is no denying that the anti-vascular endothelial growth factor A (anti-VEGF-A) monotherapy has “absolutely revolutionized our treatment of diabetic macular edema (DME).” However, there is a subset of patients in whom the anti-VEGFs are not an […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-02-19 13:50:342018-02-19 13:50:34Dr. Pravin U. Dugel – Modern Retina from Ophthalmology Times
In this interview from AAO 2017, Dr. Pravin Dugel outlines the results of two phase 3 trials of brolucizumab, a novel anti-VEGF agent for treating neovascular AMD. Brolucizumab is the smallest active unit of a human monoclonal antibody, which allows for concentrated molar dosing. The two trials, dubbed HAWK and HARRIER, suggest that extended dosing is viable. […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-02-01 18:55:252018-02-01 18:55:25Dr. Pravin Dugel: Brolucizumab: A New Anti-VEGF Agent For Wet AMD
Orbis welcomes Dr. Pravin Dugel, managing partner, Retinal Consultants of Arizona, and David Gitlin, President, UTC Aerospace Systems, to its Board of Directors. Pravin has been involved with Orbis since 2010 as a member of our Volunteer Faculty, specializing in retinal diseases including diabetic retinopathy. “I am extremely honored to join the Orbis Board of […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2018-01-12 14:44:412018-01-12 14:44:41Orbis International Welcomes New Members to its Board of Directors
Findings from neovascular AMD studies a highlight from Day 1 NEW ORLEANS – The 48-week results of the HAWK and HARRIER studies on brolucizumab (Novartis) for the treatment of neovascular age-related macular degeneration (AMD) were one of the highlights from Day 1 at Retina Subspecialty Day. Pravin Dugel, MD, (Phoenix, Ariz.) first described the antibody […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2017-12-26 16:10:092017-12-26 16:10:09Dr. Pravin Dugel – Highlights from Day 1 of Retina Subspecialty Day 2017Findings from neovascular AMD studies a highlight from Day 1
Dr. Pravin U. Dugel Treats First Patient with KSI-301
/ Uncategorized /by retinalconsultantsWe are pleased to share that the first patient in Kodiak’s phase I trial was treated by Dr. Pravin Dugel of the Retinal Consultants of Arizona. The injection was uneventful. Day 2 assessment was within normal limits with no signs of inflammation and with clear ocular media. Kodiak is A Phase I Open Label, Multi-center […]
Dr. Derek Kunimoto Discusses the CentraSight Implantable Telescope – AZTV Phoenix
/ Uncategorized /by retinalconsultantsDr. Derek Kunimoto visits the AZTV studios to discuss CentraSight’s Implantable Telescope for people with end-stage macular degeneration (wet and dry). For more information, call 602-222-2221 or visit www.CentraSight.com. Age-related macular degeneration (AMD) is the most common cause of severe vision loss in patients over 65. This condition involves a breakdown of the macula, the central […]
Ocular Surgery News: Treatment of DME poses complex choices, strives to overcome limitations
/ Uncategorized /by retinalconsultantsDr. Pravin U. Dugel – Ocular Surgery News U.S. Edition, June 25, 2018 Unmet needs and new options There are unmet needs for DME, mainly related to the high rate of poor responders and the burden of frequent injections. “There are still patients that have suboptimal improvement, so better efficacy is still an unmet need. […]
Healthy Vision Awareness!
/ Newsletters /by retinalconsultantsAccording to the American Academy of Ophthalmology, approximately 37 million adults in America have age-related macular degeneration, cataract, diabetic retinopathy, or glaucoma, all of which can cause visual impairment or blindness. However, recent studies show that making healthy choices and getting regular eye exams can help reduce a person’s risk of vision loss. In support […]
Dr. Pravin U. Dugel: Predictive Data From the HAWK and HARRIER Studies (Video)
/ Uncategorized /by retinalconsultantsPravin U. Dugel, MD, discusses the HAWK and HARRIER studies, particularly with regard to whether the disease activity assessment done at week 16 can predict which patients can be extended to 12 weeks. He also explains why this is important from a clinical standpoint. Interview from the 2018 ARVO Annual Meeting where leading experts recap […]
Retinal Consultants of Arizona is Now Hiring Ophthalmic Technicians to Travel with our Amazing Physicians and Staff!
/ Uncategorized /by retinalconsultantsThe ideal candidate will possess the following. Ophthalmology experience preferred, but willing to train the right candidate with Medical Assistant Experience. Medical Assistant must possess certification from an accredited program Must be able to work flexible hours and be able to travel via car or plane throughout the state. Photography (FA and OCT) experience helpful Must […]
Dr. Pravin U. Dugel – Modern Retina from Ophthalmology Times
/ Uncategorized /by retinalconsultantsThese novel strategies may change DME treatment paradigm By: Michelle Dalton, ELS; Reviewed by Pravin U. Dugel, MD There is no denying that the anti-vascular endothelial growth factor A (anti-VEGF-A) monotherapy has “absolutely revolutionized our treatment of diabetic macular edema (DME).” However, there is a subset of patients in whom the anti-VEGFs are not an […]
Dr. Pravin Dugel: Brolucizumab: A New Anti-VEGF Agent For Wet AMD
/ Uncategorized /by retinalconsultantsIn this interview from AAO 2017, Dr. Pravin Dugel outlines the results of two phase 3 trials of brolucizumab, a novel anti-VEGF agent for treating neovascular AMD. Brolucizumab is the smallest active unit of a human monoclonal antibody, which allows for concentrated molar dosing. The two trials, dubbed HAWK and HARRIER, suggest that extended dosing is viable. […]
Orbis International Welcomes New Members to its Board of Directors
/ Uncategorized /by retinalconsultantsOrbis welcomes Dr. Pravin Dugel, managing partner, Retinal Consultants of Arizona, and David Gitlin, President, UTC Aerospace Systems, to its Board of Directors. Pravin has been involved with Orbis since 2010 as a member of our Volunteer Faculty, specializing in retinal diseases including diabetic retinopathy. “I am extremely honored to join the Orbis Board of […]
Dr. Pravin Dugel – Highlights from Day 1 of Retina Subspecialty Day 2017Findings from neovascular AMD studies a highlight from Day 1
/ Uncategorized /by retinalconsultantsFindings from neovascular AMD studies a highlight from Day 1 NEW ORLEANS – The 48-week results of the HAWK and HARRIER studies on brolucizumab (Novartis) for the treatment of neovascular age-related macular degeneration (AMD) were one of the highlights from Day 1 at Retina Subspecialty Day. Pravin Dugel, MD, (Phoenix, Ariz.) first described the antibody […]